Can extra antibodies keep myeloma patients safer on powerful new drugs?
NCT ID NCT07094048
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This study looks at whether giving extra antibodies (immunoglobulins) can help prevent serious infections in people with multiple myeloma who are being treated with a new kind of immunotherapy called a BCMA-directed T cell engager. About 80 adults who have already tried at least one prior treatment will be enrolled. Researchers will compare two different target levels of antibodies in the blood to see which one better reduces severe infections over the first three months of therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Intégré de Cancérologie
RECRUITINGQuébec, Quebec, Canada
-
Santé Québec Chaudière-Appalaches
RECRUITINGLévis, Quebec, G6W 8A7, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Engineered immune cells take on incurable blood cancer
- New CAR T-Cell therapy targets Hard-to-Treat myeloma
- New 'Off-the-Shelf' CAR-T therapy takes on Hard-to-Treat myeloma
- Why do blood cancer patients skip home care? new study aims to find out.
- Could a simple shot replace hospital stays for myeloma patients?